Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 93,200 shares, a decline of 19.0% from the May 31st total of 115,000 shares. Based on an average daily trading volume, of 96,700 shares, the short-interest ratio is presently 1.0 days. Approximately 0.1% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Craig Hallum began coverage on shares of Indivior in a report on Wednesday, April 3rd. They set a “buy” rating and a $37.00 price objective for the company.

Indivior Stock Performance

Shares of INDV traded down $0.48 during mid-day trading on Tuesday, hitting $15.27. 118,459 shares of the company traded hands, compared to its average volume of 110,411. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.74 and a current ratio of 0.92. The stock has a 50-day moving average price of $17.25 and a two-hundred day moving average price of $18.09. Indivior has a 1 year low of $14.38 and a 1 year high of $24.90. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 1,531.00 and a beta of 0.69.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.01). The business had revenue of $284.00 million for the quarter, compared to the consensus estimate of $300.00 million. Indivior had a net margin of 0.44% and a return on equity of 842.72%. Equities analysts anticipate that Indivior will post 2 earnings per share for the current year.

Institutional Trading of Indivior

Large investors have recently added to or reduced their stakes in the business. Scopia Capital Management LP bought a new position in shares of Indivior in the third quarter worth approximately $191,743,000. Vanguard Group Inc. boosted its position in shares of Indivior by 1.6% in the third quarter. Vanguard Group Inc. now owns 5,846,354 shares of the company’s stock worth $134,875,000 after purchasing an additional 90,673 shares during the period. Norges Bank purchased a new position in shares of Indivior in the fourth quarter worth $36,011,000. UBS Group AG lifted its holdings in shares of Indivior by 71.9% in the fourth quarter. UBS Group AG now owns 826,130 shares of the company’s stock worth $12,615,000 after buying an additional 345,556 shares in the last quarter. Finally, Renaissance Group LLC lifted its holdings in shares of Indivior by 6.1% in the fourth quarter. Renaissance Group LLC now owns 103,023 shares of the company’s stock worth $1,573,000 after buying an additional 5,896 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.